Cargando…

Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer

PURPOSE: Urinary incontinence (UI) following prostate radiotherapy is a rare toxicity that adversely affects a patient’s quality of life. This study sought to evaluate the incidence of UI following stereotactic body radiation therapy (SBRT) for prostate cancer. METHODS: Between February, 2008 and Oc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Leonard N, Suy, Simeng, Wang, Hongkun, Bhagat, Aditi, Woo, Jennifer A, Moures, Rudy A, Kim, Joy S, Yung, Thomas M, Lei, Siyuan, Collins, Brian T, Kowalczyk, Keith, Dritschilo, Anatoly, Lynch, John H, Collins, Sean P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083362/ https://www.ncbi.nlm.nih.gov/pubmed/24966110 http://dx.doi.org/10.1186/1748-717X-9-148

Ejemplares similares

Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer
por: Gurka, Marie K, et al.
Publicado: (2015)

Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer
por: Arscott, W Tristram, et al.
Publicado: (2014)

Clinical Characteristics and Management of Late Urinary Symptom Flare Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Woo, Jennifer A., et al.
Publicado: (2014)

Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3))
por: Janowski, Einsley, et al.
Publicado: (2014)

Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer
por: Bhattasali, Onita, et al.
Publicado: (2014)

Proctitis following stereotactic body radiation therapy for prostate cancer
por: Joh, Daniel Y, et al.
Publicado: (2014)

Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?
por: Woo, Jennifer Ai-Lian, et al.
Publicado: (2015)

Improved Irritative Voiding Symptoms 3 Years after Stereotactic Body Radiation Therapy for Prostate Cancer
por: Rana, Zaker, et al.
Publicado: (2014)

Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience
por: Chen, Leonard N, et al.
Publicado: (2013)

Potency preservation following stereotactic body radiation therapy for prostate cancer
por: Obayomi-Davies, Olusola, et al.
Publicado: (2013)

Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Janowski, Einsley-Marie, et al.
Publicado: (2015)

Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction
por: Repka, Michael C., et al.
Publicado: (2016)

Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design
por: Paydar, Ima, et al.
Publicado: (2016)

Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)
por: Aghdam, Nima, et al.
Publicado: (2020)

Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)
por: Pepin, Abigail, et al.
Publicado: (2020)

Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer
por: Bhattasali, Onita, et al.
Publicado: (2013)

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)
por: Aghdam, Nima, et al.
Publicado: (2020)

Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging
por: Paydar, Ima, et al.
Publicado: (2015)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
por: Ju, Andrew W, et al.
Publicado: (2013)

Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer
por: Sood, Sumit, et al.
Publicado: (2013)

Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT)
por: Shah, Sarthak, et al.
Publicado: (2023)

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience
por: Mercado, Catherine, et al.
Publicado: (2016)

Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer
por: Oermann, Eric K, et al.
Publicado: (2011)

Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy
por: Lei, Siyuan, et al.
Publicado: (2011)

Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity
por: Paydar, Ima, et al.
Publicado: (2017)

Utilization of Iodinated SpaceOAR Vue™ During Robotic Prostate Stereotactic Body Radiation Therapy (SBRT) to Identify the Rectal–Prostate Interface and Spare the Rectum: A Case Report
por: Conroy, Dylan, et al.
Publicado: (2021)

Fiducial-free CyberKnife stereotactic body radiation therapy (SBRT) for single vertebral body metastases: acceptable local control and normal tissue tolerance with 5 fraction approach
por: Gill, Beant, et al.
Publicado: (2012)

Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer
por: Danner, Malika, et al.
Publicado: (2017)

Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Pepin, Abigail, et al.
Publicado: (2021)

Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
por: Kataria, Shaan, et al.
Publicado: (2017)

Scoring system predictive of survival for patients undergoing stereotactic body radiation therapy for liver tumors
por: Kress, Marie-Adele S, et al.
Publicado: (2012)

Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy
por: Pepin, Abigail, et al.
Publicado: (2021)

Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases
por: Lischalk, Jonathan W., et al.
Publicado: (2016)

Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation
por: Repka, Michael C., et al.
Publicado: (2017)

Stereotactic Body Radiation Therapy for Liver Metastases from Colorectal Cancer: Analysis of Safety, Feasibility, and Early Outcomes
por: Kress, Marie-Adele S., et al.
Publicado: (2012)

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer
por: Pepin, Abigail N., et al.
Publicado: (2022)

Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate Cancer
por: Repka, Michael C., et al.
Publicado: (2022)

Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies
por: Chen, Leonard N, et al.
Publicado: (2014)

The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Koneru, Harsha, et al.
Publicado: (2016)

CyberKnife for hilar lung tumors: report of clinical response and toxicity
por: Unger, Keith, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2dgi439nnvodqac6c8el6c318h